Vicplas International Ltd (569) Fair Value & Analysis
Healthcare · SG · Market cap 37.8M SGD
Fair value as of: Jul 3, 2026
From 2 valuation models · updated today
Share price −7.5% over the past month.
Price vs Fair Value (12 months)
12‑month range 0.0740 SGD – 0.1000 SGD · fair‑value band 0.0488 SGD – 0.0784 SGD · the 0.0740 SGD price screens above the 0.0636 SGD fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Vicplas International Ltd (569) currently trades at 0.0740 SGD, while our model-based Fair Value estimate is 0.0636 SGD — implying the stock looks roughly 14.0% overvalued today. We read business quality at 50/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Vicplas International Ltd generated revenue of 128M SGD at a net margin of -4.7%. Revenue grew 13.1% year over year. It earns a return on equity of -8.4%. Net debt stands at 14.0M SGD. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Vicplas International Ltd, an investment holding company, engages in the medical devices, and pipes and pipe fittings businesses in Singapore, Malaysia, the People's Republic of China, the United Kingdom, and Mexico. The company manufactures, trades, and distributes piping systems for various industries, including waste and potable water systems for residential homes, schools, and commercial and industrial buildings; underground electrical and internal building wire piping systems; and data and signal line piping systems by telecommunications companies. It also designs, develops, manufactures, and assembles sterile and non-sterile medical devices. Vicplas International Ltd was founded in 1993 and is based in Singapore. Vicplas International Ltd is a subsidiary of Venner Capital S.A.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Vicplas International Ltd reported revenue of 102M SGD in FY2024 versus 88.8M SGD in FY2020, a compound +3.6%/yr. Reported net income was −1.4M SGD in FY2024.
Is 569 fairly valued? → Check now
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABTT34 | R$37.76 | R$6.34 | -83% |
| Stryker Corporation S1YK34 | R$79.18 | R$43.78 | -45% |
| Medtronic plc MDT | $79.27 | $73.33 | -7% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EW | $87.45 | $41.02 | -53% |
| Siemens Healthineers AG SHL | €34.92 | €24.16 | -31% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Vicplas International Ltd (569) undervalued?
What is the fair value of 569?
What is the quality score of 569?
What is the revenue of Vicplas International Ltd (569)?
What is the net profit margin of 569?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.